Global Submucosal Injectable Composition 麻豆原创 2025 by Manufacturers, Regions, Type and Application, Forecast to 2031

Publication ID:

GIR062506980

Publication Date:

June 24, 2025

Pages:

105

Publisher:

GIR

Countries:

Global [1]

USD 3,480.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

The global Submucosal Injectable Composition market size was valued at US$ 151 million in 2024 and is forecast to a readjusted size of USD 233 million by 2031 with a CAGR of 6.5% during review period.
Submucosal Injectable Composition is designed to be used for submucosal lift of polyps, adenomas, early-stage cancers or other gastrointestinal mucosal lesions prior to excision with a snare or other endoscopic device.
With the continuous advancement of medical technology, the submucosal injectable composition has emerged as an innovative therapeutic approach gaining attention and traction. Submucosal injection involves the direct administration of drugs or therapeutic substances beneath the mucosal layer, allowing for more precise drug delivery and treatment. This method holds promise across various medical domains, particularly in the realms of gastrointestinal disorders, urological conditions, and more. As the demand for minimally invasive treatments grows, the submucosal injectable composition is poised to become a significant innovation within the medical field, tapping into substantial potential.
This report is a detailed and comprehensive analysis for global Submucosal Injectable Composition market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Submucosal Injectable Composition market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2020-2031
Global Submucosal Injectable Composition market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2020-2031
Global Submucosal Injectable Composition market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2020-2031
Global Submucosal Injectable Composition market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (US$/Unit), 2020-2025
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Submucosal Injectable Composition
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Submucosal Injectable Composition market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Boston Scientific, The Standard, EndoClot Plus, GI Supply, Cosmo Pharmaceuticals, Ovesco, Seikagaku, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
麻豆原创 Segmentation
Submucosal Injectable Composition market is split by Type and by Application. For the period 2020-2031, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
麻豆原创 segment by Type
Prefilled Syringes
Vial
麻豆原创 segment by Application
Hospitals
Clinics
Others
Major players covered
Boston Scientific
The Standard
EndoClot Plus
GI Supply
Cosmo Pharmaceuticals
Ovesco
Seikagaku
麻豆原创 segment by region, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Submucosal Injectable Composition product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Submucosal Injectable Composition, with price, sales quantity, revenue, and global market share of Submucosal Injectable Composition from 2020 to 2025.
Chapter 3, the Submucosal Injectable Composition competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Submucosal Injectable Composition breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2020 to 2031.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2020 to 2031.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2020 to 2025.and Submucosal Injectable Composition market forecast, by regions, by Type, and by Application, with sales and revenue, from 2026 to 2031.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Submucosal Injectable Composition.
Chapter 14 and 15, to describe Submucosal Injectable Composition sales channel, distributors, customers, research findings and conclusion.

Please Note - This is an on demand report and will be delivered in 2 business days (48 Hours) post payment.

Table Of Contents:

1 麻豆原创 Overview
1.1 Product Overview and Scope
1.2 麻豆原创 Estimation Caveats and Base Year
1.3 麻豆原创 Analysis by Type
1.3.1 Overview: Global Submucosal Injectable Composition Consumption Value by Type: 2020 Versus 2024 Versus 2031
1.3.2 Prefilled Syringes
1.3.3 Vial
1.4 麻豆原创 Analysis by Application
1.4.1 Overview: Global Submucosal Injectable Composition Consumption Value by Application: 2020 Versus 2024 Versus 2031
1.4.2 Hospitals
1.4.3 Clinics
1.4.4 Others
1.5 Global Submucosal Injectable Composition 麻豆原创 Size & Forecast
1.5.1 Global Submucosal Injectable Composition Consumption Value (2020 & 2024 & 2031)
1.5.2 Global Submucosal Injectable Composition Sales Quantity (2020-2031)
1.5.3 Global Submucosal Injectable Composition Average Price (2020-2031)
2 Manufacturers Profiles
2.1 Boston Scientific
2.1.1 Boston Scientific Details
2.1.2 Boston Scientific Major Business
2.1.3 Boston Scientific Submucosal Injectable Composition Product and Services
2.1.4 Boston Scientific Submucosal Injectable Composition Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.1.5 Boston Scientific Recent Developments/Updates
2.2 The Standard
2.2.1 The Standard Details
2.2.2 The Standard Major Business
2.2.3 The Standard Submucosal Injectable Composition Product and Services
2.2.4 The Standard Submucosal Injectable Composition Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.2.5 The Standard Recent Developments/Updates
2.3 EndoClot Plus
2.3.1 EndoClot Plus Details
2.3.2 EndoClot Plus Major Business
2.3.3 EndoClot Plus Submucosal Injectable Composition Product and Services
2.3.4 EndoClot Plus Submucosal Injectable Composition Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.3.5 EndoClot Plus Recent Developments/Updates
2.4 GI Supply
2.4.1 GI Supply Details
2.4.2 GI Supply Major Business
2.4.3 GI Supply Submucosal Injectable Composition Product and Services
2.4.4 GI Supply Submucosal Injectable Composition Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.4.5 GI Supply Recent Developments/Updates
2.5 Cosmo Pharmaceuticals
2.5.1 Cosmo Pharmaceuticals Details
2.5.2 Cosmo Pharmaceuticals Major Business
2.5.3 Cosmo Pharmaceuticals Submucosal Injectable Composition Product and Services
2.5.4 Cosmo Pharmaceuticals Submucosal Injectable Composition Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.5.5 Cosmo Pharmaceuticals Recent Developments/Updates
2.6 Ovesco
2.6.1 Ovesco Details
2.6.2 Ovesco Major Business
2.6.3 Ovesco Submucosal Injectable Composition Product and Services
2.6.4 Ovesco Submucosal Injectable Composition Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.6.5 Ovesco Recent Developments/Updates
2.7 Seikagaku
2.7.1 Seikagaku Details
2.7.2 Seikagaku Major Business
2.7.3 Seikagaku Submucosal Injectable Composition Product and Services
2.7.4 Seikagaku Submucosal Injectable Composition Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.7.5 Seikagaku Recent Developments/Updates
3 Competitive Environment: Submucosal Injectable Composition by Manufacturer
3.1 Global Submucosal Injectable Composition Sales Quantity by Manufacturer (2020-2025)
3.2 Global Submucosal Injectable Composition Revenue by Manufacturer (2020-2025)
3.3 Global Submucosal Injectable Composition Average Price by Manufacturer (2020-2025)
3.4 麻豆原创 Share Analysis (2024)
3.4.1 Producer Shipments of Submucosal Injectable Composition by Manufacturer Revenue ($MM) and 麻豆原创 Share (%): 2024
3.4.2 Top 3 Submucosal Injectable Composition Manufacturer 麻豆原创 Share in 2024
3.4.3 Top 6 Submucosal Injectable Composition Manufacturer 麻豆原创 Share in 2024
3.5 Submucosal Injectable Composition 麻豆原创: Overall Company Footprint Analysis
3.5.1 Submucosal Injectable Composition 麻豆原创: Region Footprint
3.5.2 Submucosal Injectable Composition 麻豆原创: Company Product Type Footprint
3.5.3 Submucosal Injectable Composition 麻豆原创: Company Product Application Footprint
3.6 New 麻豆原创 Entrants and Barriers to 麻豆原创 Entry
3.7 Mergers, Acquisition, Agreements, and Collaborations
4 Consumption Analysis by Region
4.1 Global Submucosal Injectable Composition 麻豆原创 Size by Region
4.1.1 Global Submucosal Injectable Composition Sales Quantity by Region (2020-2031)
4.1.2 Global Submucosal Injectable Composition Consumption Value by Region (2020-2031)
4.1.3 Global Submucosal Injectable Composition Average Price by Region (2020-2031)
4.2 North America Submucosal Injectable Composition Consumption Value (2020-2031)
4.3 Europe Submucosal Injectable Composition Consumption Value (2020-2031)
4.4 Asia-Pacific Submucosal Injectable Composition Consumption Value (2020-2031)
4.5 South America Submucosal Injectable Composition Consumption Value (2020-2031)
4.6 Middle East & Africa Submucosal Injectable Composition Consumption Value (2020-2031)
5 麻豆原创 Segment by Type
5.1 Global Submucosal Injectable Composition Sales Quantity by Type (2020-2031)
5.2 Global Submucosal Injectable Composition Consumption Value by Type (2020-2031)
5.3 Global Submucosal Injectable Composition Average Price by Type (2020-2031)
6 麻豆原创 Segment by Application
6.1 Global Submucosal Injectable Composition Sales Quantity by Application (2020-2031)
6.2 Global Submucosal Injectable Composition Consumption Value by Application (2020-2031)
6.3 Global Submucosal Injectable Composition Average Price by Application (2020-2031)
7 North America
7.1 North America Submucosal Injectable Composition Sales Quantity by Type (2020-2031)
7.2 North America Submucosal Injectable Composition Sales Quantity by Application (2020-2031)
7.3 North America Submucosal Injectable Composition 麻豆原创 Size by Country
7.3.1 North America Submucosal Injectable Composition Sales Quantity by Country (2020-2031)
7.3.2 North America Submucosal Injectable Composition Consumption Value by Country (2020-2031)
7.3.3 United States 麻豆原创 Size and Forecast (2020-2031)
7.3.4 Canada 麻豆原创 Size and Forecast (2020-2031)
7.3.5 Mexico 麻豆原创 Size and Forecast (2020-2031)
8 Europe
8.1 Europe Submucosal Injectable Composition Sales Quantity by Type (2020-2031)
8.2 Europe Submucosal Injectable Composition Sales Quantity by Application (2020-2031)
8.3 Europe Submucosal Injectable Composition 麻豆原创 Size by Country
8.3.1 Europe Submucosal Injectable Composition Sales Quantity by Country (2020-2031)
8.3.2 Europe Submucosal Injectable Composition Consumption Value by Country (2020-2031)
8.3.3 Germany 麻豆原创 Size and Forecast (2020-2031)
8.3.4 France 麻豆原创 Size and Forecast (2020-2031)
8.3.5 United Kingdom 麻豆原创 Size and Forecast (2020-2031)
8.3.6 Russia 麻豆原创 Size and Forecast (2020-2031)
8.3.7 Italy 麻豆原创 Size and Forecast (2020-2031)
9 Asia-Pacific
9.1 Asia-Pacific Submucosal Injectable Composition Sales Quantity by Type (2020-2031)
9.2 Asia-Pacific Submucosal Injectable Composition Sales Quantity by Application (2020-2031)
9.3 Asia-Pacific Submucosal Injectable Composition 麻豆原创 Size by Region
9.3.1 Asia-Pacific Submucosal Injectable Composition Sales Quantity by Region (2020-2031)
9.3.2 Asia-Pacific Submucosal Injectable Composition Consumption Value by Region (2020-2031)
9.3.3 China 麻豆原创 Size and Forecast (2020-2031)
9.3.4 Japan 麻豆原创 Size and Forecast (2020-2031)
9.3.5 South Korea 麻豆原创 Size and Forecast (2020-2031)
9.3.6 India 麻豆原创 Size and Forecast (2020-2031)
9.3.7 Southeast Asia 麻豆原创 Size and Forecast (2020-2031)
9.3.8 Australia 麻豆原创 Size and Forecast (2020-2031)
10 South America
10.1 South America Submucosal Injectable Composition Sales Quantity by Type (2020-2031)
10.2 South America Submucosal Injectable Composition Sales Quantity by Application (2020-2031)
10.3 South America Submucosal Injectable Composition 麻豆原创 Size by Country
10.3.1 South America Submucosal Injectable Composition Sales Quantity by Country (2020-2031)
10.3.2 South America Submucosal Injectable Composition Consumption Value by Country (2020-2031)
10.3.3 Brazil 麻豆原创 Size and Forecast (2020-2031)
10.3.4 Argentina 麻豆原创 Size and Forecast (2020-2031)
11 Middle East & Africa
11.1 Middle East & Africa Submucosal Injectable Composition Sales Quantity by Type (2020-2031)
11.2 Middle East & Africa Submucosal Injectable Composition Sales Quantity by Application (2020-2031)
11.3 Middle East & Africa Submucosal Injectable Composition 麻豆原创 Size by Country
11.3.1 Middle East & Africa Submucosal Injectable Composition Sales Quantity by Country (2020-2031)
11.3.2 Middle East & Africa Submucosal Injectable Composition Consumption Value by Country (2020-2031)
11.3.3 Turkey 麻豆原创 Size and Forecast (2020-2031)
11.3.4 Egypt 麻豆原创 Size and Forecast (2020-2031)
11.3.5 Saudi Arabia 麻豆原创 Size and Forecast (2020-2031)
11.3.6 South Africa 麻豆原创 Size and Forecast (2020-2031)
12 麻豆原创 Dynamics
12.1 Submucosal Injectable Composition 麻豆原创 Drivers
12.2 Submucosal Injectable Composition 麻豆原创 Restraints
12.3 Submucosal Injectable Composition Trends Analysis
12.4 Porters Five Forces Analysis
12.4.1 Threat of New Entrants
12.4.2 Bargaining Power of Suppliers
12.4.3 Bargaining Power of Buyers
12.4.4 Threat of Substitutes
12.4.5 Competitive Rivalry
13 Raw Material and Industry Chain
13.1 Raw Material of Submucosal Injectable Composition and Key Manufacturers
13.2 Manufacturing Costs Percentage of Submucosal Injectable Composition
13.3 Submucosal Injectable Composition Production Process
13.4 Industry Value Chain Analysis
14 Shipments by Distribution Channel
14.1 Sales Channel
14.1.1 Direct to End-User
14.1.2 Distributors
14.2 Submucosal Injectable Composition Typical Distributors
14.3 Submucosal Injectable Composition Typical Customers
15 Research Findings and Conclusion
16 Appendix
16.1 Methodology
16.2 Research Process and Data Source
16.3 Disclaimer

Companies Mentioned:

Boston Scientific
The Standard
EndoClot Plus
GI Supply
Cosmo Pharmaceuticals
Ovesco
Seikagaku

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.